« Return to News | CROs/Service Providers

Charles River and Metabolon partner on cancer research

Friday, April 6, 2012 10:54 AM

Charles River Discovery Services is partnering with Metabolon, a diagnostic products and services company based in Research Triangle Park, N.C., to enhance oncology research.

The collaboration will draw on Metabolon's in-depth analysis of metabolic data to identify both mechanism of action and biomarkers, which Charles River will combine with its preclinical oncology study expertise.

Working together, Metabolon and Charles River can provide:

  • MOA: elucidation, identification, characterization and validation of drug target candidates
  • Expertise in preclinical studies using validated in vivo and in vitro models
  • PK/PD, tumor growth delay, tumor growth inhibition, survival, combination and adjuvant study designs
  • Assessment of lead chemistries, lead ID, optimal dose, optimal combinations, sensitivity/resistance patterns and new indications for existing compounds
  • Development of biomarkers for preclinical PD, patient stratification/selection, translational models and efficacy

The new partnership will officially be announced at the upcoming American Association for Cancer Research (AACR) meeting.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.